Indefinite Delivery Contract 75D30120D08571
Award Date
7/1/20
Last Date to Order
6/30/21
Federal Agency
CDC Pittsburgh
Awardee
Dynavax Technologies Corporation
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses for disease prevention and treatment. The $58.455 million multiple-award IDC has a period of performance through June 30, 2026 and is for the procurement of adult vaccines to support the CDC's national immunization programs. Dynavax, which has experience conducting clinical trials and...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses. The contract, valued at $28,105,875.00, covers the provision of adult vaccines to support the CDC's national immunization programs. As a multiple-award IDC, the contract allows for the continued issuance of task orders to Dynavax over the performance period, which runs through June 30,...
The Centers for Disease Control and Prevention (CDC) has awarded a $56.2 million Indefinite Delivery Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, a biopharmaceutical company, for the purchase of 12 standard adult vaccines. This contract will support the CDC's immunization awardees, including state health departments, in their adult immunization programs authorized under Section 317(j) of the Public Health Service Act. The contract has a one-year period of...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs to Dynavax Technologies Corporation, a biopharmaceutical company, for the provision of drugs, pharmaceuticals, and hematology-related products. The $102 million multiple-award contract has a period of performance through September 2028. Dynavax holds several other IDIQ contract vehicles across federal agencies, allowing it to provide a range of pharmaceutical products and services including drugs, vaccines,...
This Other Transaction IDV was awarded by the Joint PEO Chemical and Biological Defense, a U.S. Department of Defense agency, to Dynavax Technologies Corporation. The $38.7 million IDV funds adaptive clinical trials focused on disease prevention and treatment, leveraging Dynavax's expertise in immunology and infectious disease research. As a prime contractor, Dynavax will provide specialized pharmaceutical products and services, including drugs, vaccines, and medical countermeasures, under...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides. The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
The federal contract IDV is an Other Transaction agreement awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Dynavax Technologies Corporation. The purpose of this $29.8 million agreement is the development of medical countermeasures for protection against pneumonic plague. Dynavax, a biopharmaceutical company focused on immune system responses, has prior experience supporting infectious disease research and medical countermeasure development through federal grants...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...